Solid Biosciences Inc. (SLDB)

10,49 +0,07 (+0,67%) A partir del 01:00PM EDT. Mercado abierto.

Solid Biosciences Inc.

500 Rutherford Avenue
Third Floor
Charlestown, MA 02129
United States
617 337 4680
https://www.solidbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 88

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Ian F. Smith A.C.A., C.P.A.	Executive Chair	75k	N/A	1966
Mr. Alexander G. Cumbo	President, CEO & Director	918,55k	N/A	1971
Mr. Ilan Ganot	Co-founder, Strategic Advisor to the CEO & Director	847,87k	N/A	1974
Mr. Kevin Tan C.F.A.	CFO & Treasurer	607,18k	N/A	1978
Mr. David Tyronne Howton Jr., J.D.	COO, General Counsel & Secretary	648,88k	N/A	1972
Ms. Annie Ganot	Co-Founder & Head of Patient Advocacy	N/A	N/A	N/A
Mr. Paul Herzich	Chief Technology Officer	N/A	N/A	1978
Dr. Jennifer Marlowe Ph.D.	Chief Scientific Officer	N/A	N/A	1977
Ms. Allison Bogosian J.D.	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Jessie Hanrahan Ph.D.	Chief Regulatory Officer	N/A	N/A	1976

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Solid Biosciences Inc., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.